Publications Office of the EU
Léčivé přípravky s účinnou látkou MIRIKIZUMAB - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Léčivé přípravky s účinnou látkou MIRIKIZUMAB

  • Published
    07/04/2025
  • Deadline
    09/05/2025
  • Awarded
    18/06/2025
  • Today
    10/07/2025
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Fakultní nemocnice Brno
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: CZ064 Jihomoravský kraj
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
46,510,728.00 CZK
Tender reference number
26/25
Description

Předmětem zadávacího řízení je uzavření rámcové kupní smlouvy na dodávky léčivých přípravků dle potřeb zadavatele.

Submission Method
Electronic via:
https://ezak.fnbrno.cz/
Tenders may be submitted
Electronic submission: required
https://ezak.fnbrno.cz/
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Criterion: Nabídková cena
Type: price
Description: Ekonomická výhodnost nabídky
Weight (percentage, exact): 100
Estimated value
Not available
Final contracted value
46,510,728.00 CZK
Award of contract
Official name: ELI LILLY ČR, s.r.o.
Postal address:
Town: Praha - Karlín
Postal code: 18600
Country:
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.